ATE357245T1 - Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs - Google Patents

Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs

Info

Publication number
ATE357245T1
ATE357245T1 AT04380188T AT04380188T ATE357245T1 AT E357245 T1 ATE357245 T1 AT E357245T1 AT 04380188 T AT04380188 T AT 04380188T AT 04380188 T AT04380188 T AT 04380188T AT E357245 T1 ATE357245 T1 AT E357245T1
Authority
AT
Austria
Prior art keywords
fviii
vwf
liquid composition
human origin
stable liquid
Prior art date
Application number
AT04380188T
Other languages
English (en)
Inventor
Gamon Salvador Grancha
Nieto Juan Ignacio Jorquera
Debart Pere Ristol
Riera Marta Massot
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Application granted granted Critical
Publication of ATE357245T1 publication Critical patent/ATE357245T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04380188T 2003-10-03 2004-09-24 Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs ATE357245T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302298A ES2229931B1 (es) 2003-10-03 2003-10-03 Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.

Publications (1)

Publication Number Publication Date
ATE357245T1 true ATE357245T1 (de) 2007-04-15

Family

ID=34307115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04380188T ATE357245T1 (de) 2003-10-03 2004-09-24 Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs

Country Status (12)

Country Link
US (1) US20050074866A1 (de)
EP (1) EP1522312B1 (de)
JP (1) JP4388875B2 (de)
AR (1) AR047756A1 (de)
AT (1) ATE357245T1 (de)
CA (1) CA2481593C (de)
DE (1) DE602004005392T2 (de)
ES (2) ES2229931B1 (de)
MX (1) MXPA04009246A (de)
PL (1) PL1522312T3 (de)
PT (1) PT1522312E (de)
UY (1) UY28531A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
EP1969004B1 (de) 2005-12-28 2011-08-10 Novo Nordisk A/S Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2244814B1 (de) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Formulierungen von rekombinantem vwf
EP2349314B1 (de) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
CN102202683A (zh) * 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2768521B1 (de) * 2011-10-18 2016-07-13 CSL Behring GmbH Kombinierte verwendung eines sulfatierten glycosaminglycans und einer hyaluronidase zur verbesserung der bioverfügbarkeit des blutgerinnungsfaktors viii
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
ES2693380T3 (es) 2013-11-08 2018-12-11 Csl Limited Nuevo método para concentrar el factor de von Willebrand o complejos de este
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
US20240189398A1 (en) 2021-04-13 2024-06-13 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
WO2023017020A1 (en) * 2021-08-11 2023-02-16 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
JPS59116228A (ja) * 1982-12-24 1984-07-05 Green Cross Corp:The 血液凝固第８因子脂肪小体製剤の製法
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
EP1194161B1 (de) * 1999-07-13 2005-11-23 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii

Also Published As

Publication number Publication date
AR047756A1 (es) 2006-02-22
CA2481593A1 (en) 2005-04-03
UY28531A1 (es) 2005-03-31
US20050074866A1 (en) 2005-04-07
PT1522312E (pt) 2007-06-19
MXPA04009246A (es) 2005-04-06
CA2481593C (en) 2009-10-20
HK1075406A1 (en) 2005-12-16
DE602004005392T2 (de) 2007-12-06
EP1522312B1 (de) 2007-03-21
PL1522312T3 (pl) 2007-08-31
ES2229931B1 (es) 2006-01-16
DE602004005392D1 (de) 2007-05-03
JP2005112855A (ja) 2005-04-28
ES2229931A1 (es) 2005-04-16
EP1522312A1 (de) 2005-04-13
ES2280924T3 (es) 2007-09-16
JP4388875B2 (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
DE602004005392D1 (de) Biologisch stabile flüssige Zusammensetzung von FVIII, vWF oder FVIII/vWF-Komplex menschlichen Ursprungs
EP1617854A4 (de) Biologisch wirksame native biomatrix-zusammensetzung
DK1440148T3 (da) Keratinocytter anvendelige som biologisk aktive substanser i behandling af sår
DE602004028359D1 (de) Reinigung von biologisch produziertem 1,3-propandiol
EP1506786A4 (de) Medizinische, ghrelin enthaltende zusammensetzungen
DE60309383D1 (de) Silberhaltige Dentalzusammensetzung
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
DE602005012267D1 (de) N von geräten
EP1552814A4 (de) Duftzusammensetzung
ATE521334T1 (de) Schweisshemmende oder desodorierende zusammensetzung
DE50207852D1 (de) Verwendung von fettalkoholethoxylaten als penetrationsförderer
ATE410175T1 (de) Co-perlchen von dha und rosmarin
ATE380813T1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
DE50311735D1 (de) Das tissue engineering von knochen
EP1434645A4 (de) Entfernung von metabolischen komponenten aus blut
DE60331183D1 (de) Kontrollierte dosierung von chlordioxid oder anderersystemen
DE602005027308D1 (de) Stabile salze von olanzapin
FR2840843B3 (fr) Structure de pince
DE602004014485D1 (de) Zusammensetzung und anwendungen von galectin-antagonisten
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60317639D1 (de) Zusammensetzungen enthaltend n-acyl-phosphatidyl-ethanolamin und/oder mischungen von n-acyl-ethanolaminen mit phosphatidinsäuren oder lysophosphatidinsäuren
EP1500693A4 (de) Schmiermittelzusammensetzung
ATE316101T1 (de) Thrombinspaltbare faktor-x-analoga
IS7166A (is) Notkun annellataðra pýrrólsambanda í meðhöndlun áliðabrjósks- eða neðanbrjósksbeinahrörnun
FI20020360A0 (fi) Biologisesti aktiivisen tuotteen uusi käyttö

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1522312

Country of ref document: EP